JPMorgan Downgrades Alnylam Pharmaceuticals (ALNY) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
FBR Capital Starts Alnylam Pharmaceuticals (ALNY) at Outperform
August 10, 2015 5:42 PM EDTFBR Capital initiates coverage on Alnylam Pharmaceuticals (NASDAQ: ALNY) with a Outperform rating and a price target of $180.00.
Analyst Christopher S. James, M.D. commented, "Given its remarkably deep, diverse, and advanced pipeline, we view Alnylam as the best RNAi play in the... More
Alnylam Pharma (ALNY) Misses Q2 EPS by 10c
August 6, 2015 4:03 PM EDTAlnylam Pharma (NASDAQ: ALNY) reported Q2 EPS of ($0.85), $0.10 worse than the analyst estimate of ($0.75). Revenue for the quarter came in at $8.69 million versus the consensus estimate of $12.64 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
... More